Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359987 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL23539268 | 0.86 | GAA (0.47) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL16115787 | 0.86 | GAA (0.47) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL16115788 | 0.86 | GAA (0.47) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL7490755 | 0.83 | MAPT (0.54) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL7490754 | 0.83 | MAPT (0.54) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL14916610 | 0.82 | GAA (0.43) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL26619017 | 0.82 | NPC1 (0.56) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL14916611 | 0.80 | RAB9A (0.44) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL21069367 | 0.79 | GAA (0.44) | SMN1; SMN2MAPTRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | SMN1; SMN2 4292/4885MAPT 2891/4885RAB9A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.